Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8889 |
High Similarity |
NPD1509 |
Clinical (unspecified phase) |
0.8616 |
High Similarity |
NPD6232 |
Discontinued |
0.8571 |
High Similarity |
NPD7473 |
Discontinued |
0.8526 |
High Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.8483 |
Intermediate Similarity |
NPD943 |
Approved |
0.8344 |
Intermediate Similarity |
NPD1934 |
Approved |
0.8323 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.8301 |
Intermediate Similarity |
NPD7390 |
Discontinued |
0.8247 |
Intermediate Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.8133 |
Intermediate Similarity |
NPD651 |
Clinical (unspecified phase) |
0.8101 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.8075 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.8075 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.8065 |
Intermediate Similarity |
NPD1511 |
Approved |
0.8063 |
Intermediate Similarity |
NPD2801 |
Approved |
0.8063 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.8061 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.8061 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.8061 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.8013 |
Intermediate Similarity |
NPD1510 |
Phase 2 |
0.8 |
Intermediate Similarity |
NPD1470 |
Approved |
0.8 |
Intermediate Similarity |
NPD1607 |
Approved |
0.7964 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7962 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7933 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7917 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7914 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7901 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7898 |
Intermediate Similarity |
NPD2532 |
Approved |
0.7898 |
Intermediate Similarity |
NPD2533 |
Approved |
0.7898 |
Intermediate Similarity |
NPD2534 |
Approved |
0.7867 |
Intermediate Similarity |
NPD1240 |
Approved |
0.7857 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.784 |
Intermediate Similarity |
NPD1465 |
Phase 2 |
0.7818 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7812 |
Intermediate Similarity |
NPD3226 |
Approved |
0.7792 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7792 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7785 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7778 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7771 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7765 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7742 |
Intermediate Similarity |
NPD970 |
Clinical (unspecified phase) |
0.773 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.7727 |
Intermediate Similarity |
NPD5408 |
Approved |
0.7727 |
Intermediate Similarity |
NPD5404 |
Approved |
0.7727 |
Intermediate Similarity |
NPD5405 |
Approved |
0.7727 |
Intermediate Similarity |
NPD5406 |
Approved |
0.7724 |
Intermediate Similarity |
NPD1201 |
Approved |
0.7716 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7706 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7684 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7683 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7661 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7657 |
Intermediate Similarity |
NPD8150 |
Discontinued |
0.7651 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7616 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7616 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7613 |
Intermediate Similarity |
NPD2796 |
Approved |
0.759 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7572 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7572 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7561 |
Intermediate Similarity |
NPD37 |
Approved |
0.7546 |
Intermediate Similarity |
NPD6599 |
Discontinued |
0.7529 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7529 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD2935 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD6535 |
Approved |
0.75 |
Intermediate Similarity |
NPD6534 |
Approved |
0.7485 |
Intermediate Similarity |
NPD3749 |
Approved |
0.7484 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7468 |
Intermediate Similarity |
NPD2800 |
Approved |
0.7452 |
Intermediate Similarity |
NPD2346 |
Discontinued |
0.7447 |
Intermediate Similarity |
NPD8151 |
Discontinued |
0.7432 |
Intermediate Similarity |
NPD9269 |
Phase 2 |
0.7429 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7425 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7425 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7425 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7425 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.7421 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7419 |
Intermediate Similarity |
NPD6651 |
Approved |
0.7399 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD7501 |
Clinical (unspecified phase) |
0.7391 |
Intermediate Similarity |
NPD6776 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6778 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6779 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6777 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6780 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6781 |
Approved |
0.7391 |
Intermediate Similarity |
NPD6782 |
Approved |
0.7377 |
Intermediate Similarity |
NPD7700 |
Phase 2 |
0.7377 |
Intermediate Similarity |
NPD7699 |
Phase 2 |
0.7368 |
Intermediate Similarity |
NPD3926 |
Phase 2 |
0.7362 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7341 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7312 |
Intermediate Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.7312 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.731 |
Intermediate Similarity |
NPD5710 |
Approved |
0.731 |
Intermediate Similarity |
NPD5711 |
Approved |
0.7303 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7288 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7288 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7278 |
Intermediate Similarity |
NPD1551 |
Phase 2 |
0.7273 |
Intermediate Similarity |
NPD3764 |
Approved |
0.7273 |
Intermediate Similarity |
NPD7435 |
Discontinued |
0.7262 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7253 |
Intermediate Similarity |
NPD6212 |
Phase 3 |
0.7253 |
Intermediate Similarity |
NPD6213 |
Phase 3 |
0.7253 |
Intermediate Similarity |
NPD6214 |
Clinical (unspecified phase) |
0.7251 |
Intermediate Similarity |
NPD1247 |
Approved |
0.725 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7241 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7235 |
Intermediate Similarity |
NPD919 |
Approved |
0.7234 |
Intermediate Similarity |
NPD8320 |
Phase 1 |
0.7234 |
Intermediate Similarity |
NPD8319 |
Approved |
0.7233 |
Intermediate Similarity |
NPD2344 |
Approved |
0.7216 |
Intermediate Similarity |
NPD5953 |
Discontinued |
0.7205 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7192 |
Intermediate Similarity |
NPD405 |
Clinical (unspecified phase) |
0.719 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7697 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7698 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7696 |
Phase 3 |
0.717 |
Intermediate Similarity |
NPD6099 |
Approved |
0.717 |
Intermediate Similarity |
NPD6100 |
Approved |
0.7169 |
Intermediate Similarity |
NPD7458 |
Discontinued |
0.7169 |
Intermediate Similarity |
NPD5808 |
Clinical (unspecified phase) |
0.7162 |
Intermediate Similarity |
NPD9268 |
Approved |
0.7152 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7152 |
Intermediate Similarity |
NPD920 |
Approved |
0.7151 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD7870 |
Phase 2 |
0.7143 |
Intermediate Similarity |
NPD7871 |
Phase 2 |
0.7134 |
Intermediate Similarity |
NPD5401 |
Approved |
0.712 |
Intermediate Similarity |
NPD7701 |
Phase 2 |
0.7107 |
Intermediate Similarity |
NPD3748 |
Approved |
0.7107 |
Intermediate Similarity |
NPD2799 |
Discontinued |
0.7099 |
Intermediate Similarity |
NPD7003 |
Approved |
0.7097 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.707 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.707 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7069 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD1164 |
Approved |
0.7055 |
Intermediate Similarity |
NPD2309 |
Approved |
0.7047 |
Intermediate Similarity |
NPD7874 |
Approved |
0.7047 |
Intermediate Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.7037 |
Intermediate Similarity |
NPD6823 |
Phase 2 |
0.7037 |
Intermediate Similarity |
NPD1243 |
Approved |
0.7016 |
Intermediate Similarity |
NPD7211 |
Clinical (unspecified phase) |
0.7012 |
Intermediate Similarity |
NPD3300 |
Phase 2 |
0.701 |
Intermediate Similarity |
NPD7801 |
Approved |
0.7006 |
Intermediate Similarity |
NPD7286 |
Phase 2 |
0.6994 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6979 |
Remote Similarity |
NPD6973 |
Clinical (unspecified phase) |
0.6978 |
Remote Similarity |
NPD8434 |
Phase 2 |
0.6968 |
Remote Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD9493 |
Approved |
0.6944 |
Remote Similarity |
NPD4419 |
Clinical (unspecified phase) |
0.6943 |
Remote Similarity |
NPD2313 |
Discontinued |
0.6928 |
Remote Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD642 |
Clinical (unspecified phase) |
0.6923 |
Remote Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.6918 |
Remote Similarity |
NPD447 |
Suspended |
0.6914 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6914 |
Remote Similarity |
NPD1471 |
Phase 3 |
0.6909 |
Remote Similarity |
NPD643 |
Clinical (unspecified phase) |
0.6903 |
Remote Similarity |
NPD2798 |
Approved |
0.6889 |
Remote Similarity |
NPD7240 |
Approved |
0.6883 |
Remote Similarity |
NPD1283 |
Approved |
0.6879 |
Remote Similarity |
NPD4625 |
Phase 3 |
0.6867 |
Remote Similarity |
NPD9545 |
Approved |
0.6867 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6863 |
Remote Similarity |
NPD3972 |
Approved |
0.6862 |
Remote Similarity |
NPD8090 |
Clinical (unspecified phase) |
0.6837 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6837 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6835 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6826 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6821 |
Remote Similarity |
NPD4196 |
Clinical (unspecified phase) |
0.6821 |
Remote Similarity |
NPD1651 |
Approved |
0.6818 |
Remote Similarity |
NPD7229 |
Phase 3 |
0.6816 |
Remote Similarity |
NPD6020 |
Phase 2 |
0.681 |
Remote Similarity |
NPD7266 |
Discontinued |
0.6797 |
Remote Similarity |
NPD1547 |
Clinical (unspecified phase) |
0.6796 |
Remote Similarity |
NPD7685 |
Pre-registration |
0.6786 |
Remote Similarity |
NPD6273 |
Approved |
0.6776 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6776 |
Remote Similarity |
NPD3019 |
Approved |
0.6774 |
Remote Similarity |
NPD1876 |
Approved |
0.6772 |
Remote Similarity |
NPD5952 |
Clinical (unspecified phase) |
0.6765 |
Remote Similarity |
NPD3455 |
Phase 2 |
0.676 |
Remote Similarity |
NPD7177 |
Discontinued |
0.675 |
Remote Similarity |
NPD3620 |
Phase 2 |
0.675 |
Remote Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.6748 |
Remote Similarity |
NPD2438 |
Suspended |
0.6731
|
Remote Similarity |
NPD1203 |
Approved |